StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
0329.KL$0.23+0.00%
Fair $0.23+0.0%

0329.KL

Metro Healthcare Berhad

Healthcare / Medical Care FacilitiesKuala Lumpur

$0.23

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $0.23Fund rank 39/100 · Data gapFallback financials|
SA 58/C
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 23% · confianza 25%

FCF escenarios

weak_data · normalized FCF $7.4M · quality 83.7/100

Data gap 39/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 86/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

58/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 0329.KLLocal privado en este navegador · Metro Healthcare Berhad
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$220M

P/E

22.5x

↑

EV/EBITDA

12.7x

↑

ROE

7.8%

↑

Gross Margin

37.6%

↓

Debt/Equity

0.19

↓
52-Week Range$0
$0$0

TradingView lightweight chart

0329.KL price, volumen y niveles de valoración

Último $0.225Periodo +125.0%
Fair value: $0.225

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+7.8%

FCF CAGR

+17.6%

FCF margin

15.1%

FCF / Net income

1.30x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $50.4M · net income $5.9M · FCF $7.6M

2022-FY → 2025-FY

Gross margin

37.6%-2.1% pts

Operating margin

13.7%+3.7% pts

Net margin

11.6%-0.8% pts

FCF margin

15.1%+3.5% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$50.4M$50.4M$48.6M$44.7M$40.3M
Net Income$5.9M$5.9M$4.6M$6.2M$5.0M
EBITDA$14.4M$14.4M$13.3M$14.3M$14.6M
EPS——0.000.010.01
Gross Margin37.6%37.6%40.5%40.5%39.7%
Operating Margin13.7%13.7%15.2%19.8%10.1%
Net Margin11.6%11.6%9.4%14.0%12.5%
Balance Sheet
Debt/Equity0.190.190.210.480.29
Current Ratio7.527.52———
Cash Flow
Free Cash Flow$7.6M$7.6M$5.6M$7.4M$4.7M
Returns
ROE7.8%7.8%6.0%16.7%14.2%
Valuation
P/E22.5022.5048.9482.89111.93
EV/EBITDA12.7412.7414.2736.4438.34
P/B2.932.932.9813.8615.95
Growth & Yield
Revenue Growth3.6%3.6%8.9%11.0%—
EPS Growth——-38.2%25.1%—
Dividend Yield2.2%2.2%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +12.0%

Total return

+12.0%

Start / end P/E

n/dx → n/dx

EPS bridge

0.00 → n/d

Residual

+9.8%

EPS growthn/d
Multiple reratingn/d
Dividend+2.2%
Residual / FX / buybacks / cross-term+9.8%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.